Cristina Pascual-Izquierdo, Mª Jose Llacer-Ferrandis, Almudena de-la-Iglesia, Silvia Monsalvo-Saornil, María Menor-Gómez, Juan Jose Gil-Fernández, Esther Chica-Gullon, María Teresa Álvarez-Román, Gloria Perez-Segura, Denis Zafra, Ariana Ortuzar-Pasalodos, Isabel Teresa González-Gascón-Y-Marín, Gemma Moreno, Teresa Arquero-Portero, Marta Moreno-Carbonell, Nuria Revilla
{"title":"Avatrombopag in adults with immune thrombocytopenia: A multicentre real-life observational study in Madrid, Spain (AVAMAD study).","authors":"Cristina Pascual-Izquierdo, Mª Jose Llacer-Ferrandis, Almudena de-la-Iglesia, Silvia Monsalvo-Saornil, María Menor-Gómez, Juan Jose Gil-Fernández, Esther Chica-Gullon, María Teresa Álvarez-Román, Gloria Perez-Segura, Denis Zafra, Ariana Ortuzar-Pasalodos, Isabel Teresa González-Gascón-Y-Marín, Gemma Moreno, Teresa Arquero-Portero, Marta Moreno-Carbonell, Nuria Revilla","doi":"10.1111/bjh.19975","DOIUrl":null,"url":null,"abstract":"<p><p>Immune thrombocytopenia (ITP) is a rare acquired disorder where thrombopoietin-receptor agonists have become mainstays of ITP treatment. With the recent approval of avatrombopag (AVA), real-world studies are essential to evaluate its efficacy and safety. Our study of 66 adult ITP patients treated with AVA showed a high response rate. After starting AVA, 74.2% did not require rescue medications, with minimal adverse effects. Additionally, 56.0% of patients reduced other ITP medications, and all patients aged ≥65 years responded to AVA. Results should be confirmed in larger studies, but AVA appears to be an effective and safe treatment for ITP patients.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/bjh.19975","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Immune thrombocytopenia (ITP) is a rare acquired disorder where thrombopoietin-receptor agonists have become mainstays of ITP treatment. With the recent approval of avatrombopag (AVA), real-world studies are essential to evaluate its efficacy and safety. Our study of 66 adult ITP patients treated with AVA showed a high response rate. After starting AVA, 74.2% did not require rescue medications, with minimal adverse effects. Additionally, 56.0% of patients reduced other ITP medications, and all patients aged ≥65 years responded to AVA. Results should be confirmed in larger studies, but AVA appears to be an effective and safe treatment for ITP patients.
期刊介绍：
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
